TEMENOS
12.1.2021 08:32:36 CET | Business Wire | Press release
Temenos (SIX: TEMN), the banking software company, today announced that Komerční banka, a member of the Société Générale Group and one of the largest financial institutions in the Czech Republic, has selected Temenos Transact to modernize its retail and corporate banking.
After a rigorous selection process, the bank selected Temenos’ next-generation core banking platform for its modernization journey in the area of account management. Temenos will decrease time to market for innovative current, savings and deposit account services and lending products as well as streamline straight-through-processing across its retail and corporate banking operations.
Komerční banka is a universal bank providing a wide range of services in retail, SME, corporate and investment banking to more than 1.6 million customers. Komerční banka’s services are accessible through a network of more than 240 branches as well as digital banking channels including mobile and internet banking. The modernization of its core system with Temenos constitutes a crucial step in Komerční banka’s long-term strategy to reinforce its leadership in digital banking in the Czech Republic.
Simplification of IT systems and consolidation on Temenos’ platform will enable Komerční banka to bring new products to market faster. It will also enable Komerční banka to deliver an enhanced service with real-time processing and acceleration of customer journeys in retail and corporate segments. Additionally, Temenos’ flexible and agile technology will allow Komerční banka to rationalize its product portfolio and provide a foundation to future-proof business growth.
Komerční banka ranks among the leading banking institutions in the Czech Republic and in Central and Eastern Europe. It has a reputation as a digital leader and Temenos API-first technology will allow Komerční banka to accelerate the development and integration of new services as it continues to improve the experience and value it delivers to customers.
A key factor in Komerční banka’s decision to select Temenos was the rich banking functionality of Temenos Transact for retail and corporate banking. Komerční banka offers a diverse range of deposit, credit, lending and payment services for individuals, small business and corporate customers.
Jan Juchelka, Komerční banka’s Chairman and CEO, commented: “We have selected the new software platform because of its robust design and also its open and modern architecture. We are delighted to have an opportunity to benefit from the expertise and experience of Temenos, whose clients include the world’s largest financial institutions. It is important for us to work with a partner who shares our approach to innovation and who will help us to use the latest technologies now and in the future. Our objective is to achieve the highest level of customer satisfaction in the market. Thanks to the new software platform we can work in agile, flexible, and effective manner and so, ultimately, innovate faster and bring an added value to our clients.”
Jean-Michel Hilsenkopf, Chief Operating Officer, Temenos: “Komerční banka is a large financial institution that has shown a real commitment and appetite for innovation to deliver a market-leading service to its customers. Now, with Temenos cloud-native technology, it can supercharge these efforts and bring new products to market much faster and on a lower cost base. With heightened competition and new regulation putting pressure on margins across the industry, this capability is a huge competitive advantage that will help Komerční banka to grow its client base and ultimately increase market share and profits. Temenos has a long term strategic relationship with Société Générale and Komerční banka is a new step in this long and successful partnership.”
Temenos Transact was recently recognized as a leader in The Forrester Wave™: Digital Banking Processing Platforms Q3 2020 for Corporate Banking and Retail Banking .
– Ends –
About Temenos
Temenos AG (SIX: TEMN) is the world’s leader in banking software. Over 3,000 banks across the globe, including 41 of the top 50 banks, rely on Temenos to process both the daily transactions and client interactions of more than 1.2bn banking customers. Temenos offers cloud-native, cloud-agnostic and AI-driven front office, core banking, payments and fund administration software enabling banks to deliver frictionless, omnichannel customer experiences and gain operational excellence.
Temenos software is proven to enable its top-performing clients to achieve cost-income ratios of 26.8% half the industry average and returns on equity of 29%, three times the industry average. These clients also invest 51% of their IT budget on growth and innovation versus maintenance, which is double the industry average, proving the banks’ IT investment is adding tangible value to their business.
For more information, please visit www.temenos.com .
About Komerční banka
Komerční banka is the parent company of KB Group and a member of the Société Générale Group. KB ranks among the leading banking institutions in the Czech Republic, as well as in Central and Eastern Europe. It is a universal bank providing a wide range of services in retail, corporate, and investment banking. Member companies of Komerční banka Group provide additional specialised financial services, such as pension savings and building society schemes, leasing, factoring, consumer lending, and insurance. These are accessible through KB’s branch network, its direct banking channels, and the subsidiaries’ own sales networks. The Bank also provides services in the Slovak Republic through its branch focused on serving corporate clients as well as through selected subsidiaries.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210111005018/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom